



Tuberculosis Country Profile 2021 China

Source: Global tuberculosis report 2021. Geneva: World Health Organization

Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.

Tuberculosis profile: China

Population 2020: 1 439 million

Estimates of TB burden*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	842 000 (717 000-978 000)	59 (50-68)
HIV-positive TB incidence	12 000 (10 000-14 000)	0.84 (0.71-0.98)
HIV-negative TB mortality	30 000 (27 000-33 000)	2.1 (1.9-2.3)
HIV-positive TB mortality	2 100 (1 600-2 700)	0.15 (0.11-0.19)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2020	74% (64-87)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	4% (3-5)

TB case notifications, 2020

Total new and relapse	624 715
- % tested with rapid diagnostics at time of diagnosis	45%
- % with known HIV status	68%
- % pulmonary	95%
- % bacteriologically confirmed [^]	55%
- % children aged 0-14 years	1%
- % women (aged ≥15 years)	31%
- % men (aged ≥15 years)	68%
Total cases notified	633 156

TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	6 076	1.4%
- on antiretroviral therapy	5 287	87%

Drug-resistant TB care**, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	83%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	97%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	16 343
Patients started on treatment - MDR/RR-TB ^{^^^}	13 250
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	1 185
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	947
MDR/RR-TB cases tested for resistance to any fluoroquinolone	4 726

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	94%	711 965
Previously treated cases, excluding relapse, registered in 2019	87%	6 204
HIV-positive TB cases registered in 2019	71%	7 715
MDR/RR-TB cases started on second-line treatment in 2018	54%	8 965
XDR-TB cases started on second-line treatment in 2018		

TB preventive treatment, 2020


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing

National TB budget, 2021 (US\$ millions)	901
- Funding source, domestic	88%
- Funding source, international	0.021%
- unfunded	12%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




HIV-negative TB mortality

(Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2020

(Number)




Cases attributable to five risk factors, 2020

(Number)



Total budget

(US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
 ** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
 ^ Calculated for pulmonary cases only
 ^^ Includes cases with unknown previous TB treatment history
 ^^ Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed